Classifying MMR variants: Time for revised nomenclature in Lynch syndrome

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2280-2282

  You, Y Nancy ^a   Vilar, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MLH1;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CLASSIFICATION; CANCER SCREENING; GENE EXPRESSION; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MHL1 GENE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; HUMANS; NUCLEAR PROTEINS;

EID: 84877091276     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0392     Document Type: Article

References (12)

1. Hinrichsen I, Brieger A, Trojan J, Zeuzem S, Nilbert M, Plotz G. Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch Syndrome diagnosis. Clin Cancer Res 2013;19:2432-41.
2. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
3. Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999;282:247-53. (Pubitemid 29343167)
4. Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr Opin Genet Dev 2010;20:315-23.
5. Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. Hum Mutat 2013;34:200-9.
6. Borras E, Pineda M, Brieger A, Hinrichsen I, Gomez C, Navarro M, et al. Comprehensive functional assessment of MLH1 variants of unknown significance. Hum Mutat 2012;33:1576-88.
7. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966;117:206-12.
8. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
9. Colas C, Coulet F, Svrcek M, Collura A, Flejou JF, Duval A, et al. Lynch or not Lynch? Is that always a question? Adv Cancer Res 2012;113:121-66.
10. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;293:1979-85. (Pubitemid 40570891)
11. Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center. J Clin Oncol 2013;31:1336-40.
12. Rodriguez-Soler M, Pérez-Carbonell L, Guarinos C, Zapater P, CastillejoA, Barberá VM, et al. Risk of cancer in cases of suspected Lynchsyndrome without germline mutation. Gastroenterology 2013 Jan 24. [Epub ahead of print].